Danaher to launch AI autonomous lab in early 2027

Danaher's planned lab is the latest example of pharmaceutical research moving toward hybrid environments that combine AI, robotics and laboratory automation, where closed-loop systems can plan, execute and analyse experiments with minimal human intervention. The company says the facility, based at Abcam, will connect AI-designed affinity reagents with automated building and testing, then feed results back into the AI model — a continuous design-make-test-learn cycle. Robotic automation and device orchestration for the workflow were developed with Automata, which Danaher invested in through Automata's US$45m Series C in January 2026.

Danaher is not alone in pursuing this direction. Roche has said it is developing autonomous, AI-driven laboratories to accelerate R&D and drug discovery, and is targeting up to 20 new molecular entities by 2030. Among AI-native drug discovery companies, Recursion Pharmaceuticals operates automated laboratories as part of Recursion OS that can run up to two million experiments a week, while Isomorphic Labs and Insilico Medicine have each built AI-first approaches connecting models with automated experimentation and feedback.

The lab also reflects a broader pattern in Danaher's external relationships: its partnership with AstraZeneca, established in 2025, focuses on novel diagnostic tools including AI-powered diagnostics, and Danaher Ventures has described Innovaccer as a strategic AI-centric partner with potential for co-development, co-marketing and co-distribution. Whether the Cambridge lab becomes a template for Danaher's wider portfolio remains to be seen, with operations not expected until early 2027.